Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus (Q38573559)

4 September 2017

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus (English)

1 reference

4 September 2017

1 reference

Norm Rosenthal

1

1 reference

4 September 2017

Gary Meininger

2

1 reference

4 September 2017

Kirk Ways

3

1 reference

4 September 2017

David Polidori

4

1 reference

4 September 2017

Mehul Desai

5

1 reference

4 September 2017

Rong Qiu

6

1 reference

4 September 2017

Maria Alba

7

1 reference

4 September 2017

Frank Vercruysse

8

1 reference

4 September 2017

Dainius Balis

9

1 reference

4 September 2017

Wayne Shaw

10

1 reference

4 September 2017

Robert Edwards

11

1 reference

4 September 2017

Scott Bull

12

1 reference

4 September 2017

Nicholas Di Prospero

13

1 reference

4 September 2017

Sue Sha

14

1 reference

4 September 2017

Paul Rothenberg

15

1 reference

4 September 2017

William Canovatchel

16

1 reference

4 September 2017

Keith Demarest

17

1 reference

4 September 2017

language of work or name

English

0 references

publication date

25 August 2015

1 reference

Annals of the New York Academy of Sciences

4 September 2017

1 reference

4 September 2017

1358

1 reference

4 September 2017

28-43

1 reference

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

4 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Standards of medical care in diabetes--2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

SGLT2 inhibition--a novel strategy for diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Renal glucose reabsorption inhibitors to treat diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Canagliflozin: effects in overweight and obese subjects without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12852

21 January 2018

Identifiers

DOI

10.1111/NYAS.12852

1 reference

4 September 2017

1 reference